TY - JOUR
T1 - Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer
T2 - Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network
AU - Bonsang-Kitzis, Hélène
AU - Panchbhaya, Nabilah
AU - Bats, Anne Sophie
AU - Pujade-Lauraine, Eric
AU - Pautier, Patricia
AU - Ngô, Charlotte
AU - Le Frère-Belda, Marie Aude
AU - Kalbacher, Elsa
AU - Floquet, Anne
AU - Berton-Rigaud, Dominique
AU - Lefeuvre-Plesse, Claudia
AU - Fabbro, Michel
AU - Ray-Coquard, Isabelle
AU - Lécuru, Fabrice
N1 - Publisher Copyright:
© 2022 by the authors. Li-censee MDPI, Basel, Switzerland.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) and to assess the survival (progression-free (PFS) and overall survival (OS)) in patients with advanced LGSOC. We retrospectively analyzed advanced LGSOC from a nationwide registry (January 2000 to July 2017). A total of 127 patients were included (48% PDS and 35% NACT-IDS). Peritoneal carcinomatosis was more severe (p = 0.01 to 0.0001, according to sites), surgery more complex (p = 0.03) and late postoperative morbidity more frequent (p = 0.03) and more severe in the NACT-IDS group. PFS and OS were similar in patients with CC0 and CC1 residual disease after PDS or IDS. Prognosis was poorest for NACT-IDS patients with CC2/CC3 resection (PFS: HR = 2.31, IC95% (1.3–4.58); p = 0.005; OS: HR = 4.98, IC95% (1.59–15.61); p = 0.006). NACT has no benefit in terms of surgical outputs in patients with advanced LGSOC. Patients with complete resection or minimal residual disease (CC0 and CC1) have similar prognoses. On the other hand, patients with CC2 and more residual disease have similar survival rates compared to nonoperated patients. Primary cytoreduction with complete or with minimal residuals should be preferred when feasible.
AB - The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) and to assess the survival (progression-free (PFS) and overall survival (OS)) in patients with advanced LGSOC. We retrospectively analyzed advanced LGSOC from a nationwide registry (January 2000 to July 2017). A total of 127 patients were included (48% PDS and 35% NACT-IDS). Peritoneal carcinomatosis was more severe (p = 0.01 to 0.0001, according to sites), surgery more complex (p = 0.03) and late postoperative morbidity more frequent (p = 0.03) and more severe in the NACT-IDS group. PFS and OS were similar in patients with CC0 and CC1 residual disease after PDS or IDS. Prognosis was poorest for NACT-IDS patients with CC2/CC3 resection (PFS: HR = 2.31, IC95% (1.3–4.58); p = 0.005; OS: HR = 4.98, IC95% (1.59–15.61); p = 0.006). NACT has no benefit in terms of surgical outputs in patients with advanced LGSOC. Patients with complete resection or minimal residual disease (CC0 and CC1) have similar prognoses. On the other hand, patients with CC2 and more residual disease have similar survival rates compared to nonoperated patients. Primary cytoreduction with complete or with minimal residuals should be preferred when feasible.
KW - advanced stage
KW - low-grade serous ovarian cancer
KW - neoadjuvant chemotherapy
KW - surgery
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85129634717&partnerID=8YFLogxK
U2 - 10.3390/cancers14092345
DO - 10.3390/cancers14092345
M3 - Article
AN - SCOPUS:85129634717
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 9
M1 - 2345
ER -